司美格鲁肽注射液治疗成人2型糖尿病的临床综合评价
Comprehensive clinical evaluation of semaglutide injection for the treatment of diabetes mellitus type 2 in adults
贺兰芝 1周鹏翔 2秦永洁 1林春燕 1区燕婷 1何颖 3李桂德 1周甘平1
作者信息
- 1. 广西壮族自治区江滨医院 药学部,南宁 530021
- 2. 北京大学第三医院 药剂科,北京 100191;北京大学医学部 药物评价中心,北京 100191
- 3. 广西壮族自治区江滨医院 内分泌科,南宁 530021
- 折叠
摘要
目的 对司美格鲁肽注射液进行临床综合评价,为其临床决策和合理用药提供参考.方法 采用系统性文献综述、问卷调研等方法,对司美格鲁肽注射液的有效性、安全性、经济性、创新性、适宜性和可及性进行定性与定量分析.结果 有效性和安全性方面,司美格鲁肽可显著降低糖化血红蛋白(HbA1c)、空腹血糖和体质量,提高HbA1c的达标率.其总体安全性较好,低血糖风险低,胃肠道不良反应发生风险高于或与对照药物相当.经济性方面,司美格鲁肽比度拉糖肽和洛塞那肽更具有经济学优势.司美格鲁肽被国内外临床指南推荐,具有良好的临床创新性.在适宜性方面,司美格鲁肽具有较好的给药便利性、依从性等.在可及性方面,司美格鲁肽的可负担性较好,但中标区域数和医疗机构的配备率较低,存在短缺情况.结论 司美格鲁肽注射液具有良好的有效性、安全性、经济性、创新性、适宜性和可负担性,可获得性有待进一步改善.
Abstract
Objective Comprehensive clinical evaluation of semaglutide injection was conducted to provide a reference for clinical decision-making and rational use of this drug.Methods A systematic literature review and questionnaire surveys were used,to perform a qualitative and quantitative analysis of the efficacy,safety,economy,innovation,suitability,and ac-cessibility of the drugs.Results In terms of efficacy and safety,semaglutide significantly reduces glycated hemoglobin A1c(HbA1c)levels,fasting blood glucose,and body weight,while also improving the achievement rate of HbA1c targets.The overall safety of semaglutide injection was good,with a low risk of hypoglycemia,although the risk of gastrointestinal adverse reactions was higher or similar to other antidiabetic drugs.In terms of economy,semaglutide injection demonstrates greater economic advantages compared to dulaglutide and loxenatide.With good clinical innovation,semaglutide injection was recom-mended by clinical guidelines both domestically and internationally.In terms of dosing convenience and compliance,it exhibits good suitability for use.Semaglutide injection exhibits good affordability,but the number of bid-winning areas and the rate of medical institution distribution were relatively low,leading to shortages.Conclusion Semaglutide injection demonstrates good efficacy,safety,economy,innovation,suitability,and affordability.However,its availability needs to be further improved.
关键词
司美格鲁肽/2型糖尿病/临床综合评价/胰高血糖素样肽-1受体Key words
semaglutide/diabetes mellitus type 2/comprehensive clinical evaluation/glucagon-like peptide-1引用本文复制引用
基金项目
2022-2023年度广西壮族自治区卫生健康委药品临床综合评价课题(YPPJ003)
出版年
2024
NETL
NSTL
万方数据